Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2017, Article ID 6162845, 7 pages
Clinical Study

A First Report on [18F]FPRGD2 PET/CT Imaging in Multiple Myeloma

1CHU of Liege, Nuclear Medicine and Oncological Imaging Division, Medical Physics Department, Liege, Belgium
2CHU of Liege, Department of Clinical Hematology, Liege, Belgium
3Molecular Imaging Program at Stanford (MIPS), Radiology Department, Stanford University, Stanford, CA, USA

Correspondence should be addressed to Jo Caers;

Received 19 March 2017; Revised 15 May 2017; Accepted 13 June 2017; Published 27 July 2017

Academic Editor: Xuelei Ma

Copyright © 2017 Nadia Withofs et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


An observational study was set up to assess the feasibility of FPRG PET/CT for imaging patients with multiple myeloma (MM) and to compare its detection rate with low dose CT alone and combined NaF/FDG PET/CT images. Four patients (2 newly diagnosed patients and 2 with relapsed MM) were included and underwent whole-body PET/CT after injection of FPRG. The obtained images were compared with results of low dose CT and already available results of a combined NaF/FDG PET/CT. In total, 81 focal lesions (FLs) were detected with PET/CT and an underlying bone destruction or fracture was seen in 72 (89%) or 8 (10%) FLs, respectively. Fewer FLs (54%) were detected by FPRG PET/CT compared to low dose CT (98%) or NaF/FDG PET/CT (70%) and all FLs detected with FPRG PET were associated with an underlying bone lesion. In one newly diagnosed patient, more FPRG positive lesions were seen than NaF/FDG positive lesions. This study suggests that FPRG PET/CT might be less useful for the detection of myeloma lesions in patients with advanced disease as all FLs with FPRG uptake were already detected with CT alone.